99 related articles for article (PubMed ID: 20088749)
1. A review of erlotinib--an oral, selective epidermal growth factor receptor tyrosine kinase inhibitor.
Iyer R; Bharthuar A
Expert Opin Pharmacother; 2010 Feb; 11(2):311-20. PubMed ID: 20088749
[TBL] [Abstract][Full Text] [Related]
2. Skin problems and EGFR-tyrosine kinase inhibitor.
Kozuki T
Jpn J Clin Oncol; 2016 Apr; 46(4):291-8. PubMed ID: 26826719
[TBL] [Abstract][Full Text] [Related]
3. Role of erlotinib in first-line and maintenance treatment of advanced non-small-cell lung cancer.
Reguart N; Cardona AF; Rosell R
Cancer Manag Res; 2010 Jun; 2():143-56. PubMed ID: 21188105
[TBL] [Abstract][Full Text] [Related]
4. Erlotinib in the treatment of advanced pancreatic cancer.
Kelley RK; Ko AH
Biologics; 2008 Mar; 2(1):83-95. PubMed ID: 19707431
[TBL] [Abstract][Full Text] [Related]
5. Metabolism considerations for kinase inhibitors in cancer treatment.
Duckett DR; Cameron MD
Expert Opin Drug Metab Toxicol; 2010 Oct; 6(10):1175-93. PubMed ID: 20684746
[TBL] [Abstract][Full Text] [Related]
6. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.
Rosell R; Carcereny E; Gervais R; Vergnenegre A; Massuti B; Felip E; Palmero R; Garcia-Gomez R; Pallares C; Sanchez JM; Porta R; Cobo M; Garrido P; Longo F; Moran T; Insa A; De Marinis F; Corre R; Bover I; Illiano A; Dansin E; de Castro J; Milella M; Reguart N; Altavilla G; Jimenez U; Provencio M; Moreno MA; Terrasa J; Muñoz-Langa J; Valdivia J; Isla D; Domine M; Molinier O; Mazieres J; Baize N; Garcia-Campelo R; Robinet G; Rodriguez-Abreu D; Lopez-Vivanco G; Gebbia V; Ferrera-Delgado L; Bombaron P; Bernabe R; Bearz A; Artal A; Cortesi E; Rolfo C; Sanchez-Ronco M; Drozdowskyj A; Queralt C; de Aguirre I; Ramirez JL; Sanchez JJ; Molina MA; Taron M; Paz-Ares L;
Lancet Oncol; 2012 Mar; 13(3):239-46. PubMed ID: 22285168
[TBL] [Abstract][Full Text] [Related]
7. One-Pot Synthesis of 1-Thia-4-azaspiro[4.4/5]alkan-3-ones via Schiff Base: Design, Synthesis, and Apoptotic Antiproliferative Properties of Dual EGFR/BRAF
Al-Wahaibi LH; El-Sheref EM; Hammouda MM; Youssif BGM
Pharmaceuticals (Basel); 2023 Mar; 16(3):. PubMed ID: 36986566
[TBL] [Abstract][Full Text] [Related]
8. Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead-A Systematic Review.
Damaskos C; Garmpis N; Dimitroulis D; Garmpi A; Psilopatis I; Sarantis P; Koustas E; Kanavidis P; Prevezanos D; Kouraklis G; Karamouzis MV; Marinos G; Kontzoglou K; Antoniou EA
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430594
[TBL] [Abstract][Full Text] [Related]
9. TNBC Therapeutics Based on Combination of Fusarochromanone with EGFR Inhibitors.
Carroll N; Youngblood R; Smith A; Dragoi AM; Salvatore BA; Mahdavian E
Biomedicines; 2022 Nov; 10(11):. PubMed ID: 36428475
[TBL] [Abstract][Full Text] [Related]
10. Small Molecule Inhibitors for Hepatocellular Carcinoma: Advances and Challenges.
Kamal MA; Mandour YM; Abd El-Aziz MK; Stein U; El Tayebi HM
Molecules; 2022 Aug; 27(17):. PubMed ID: 36080304
[TBL] [Abstract][Full Text] [Related]
11. Erlotinib overcomes paclitaxel-resistant cancer stem cells by blocking the EGFR-CREB/GRβ-IL-6 axis in MUC1-positive cervical cancer.
Lv Y; Cang W; Li Q; Liao X; Zhan M; Deng H; Li S; Jin W; Pang Z; Qiu X; Zhao K; Chen G; Qiu L; Huang L
Oncogenesis; 2019 Nov; 8(12):70. PubMed ID: 31772161
[TBL] [Abstract][Full Text] [Related]
12. Alterations in Pharmacokinetics of Gemcitabine and Erlotinib by Concurrent Administration of Hyangsayukgunja-Tang, a Gastroprotective Herbal Medicine.
Kim TH; Shin S; Kim S; Bulitta JB; Weon KY; Joo SH; Ma E; Yoo SD; Park GY; Kwon DR; Jeong SW; Lee DY; Shin BS
Molecules; 2017 Sep; 22(9):. PubMed ID: 28891960
[TBL] [Abstract][Full Text] [Related]
13. Locoregional and systemic therapy for hepatocellular carcinoma.
Gbolahan OB; Schacht MA; Beckley EW; LaRoche TP; O'Neil BH; Pyko M
J Gastrointest Oncol; 2017 Apr; 8(2):215-228. PubMed ID: 28480062
[TBL] [Abstract][Full Text] [Related]
14. Interventions for the treatment of oral and oropharyngeal cancers: targeted therapy and immunotherapy.
Chan KK; Glenny AM; Weldon JC; Furness S; Worthington HV; Wakeford H
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD010341. PubMed ID: 26625332
[TBL] [Abstract][Full Text] [Related]
15. [Adverse events of afatinib as first-line treatment for five cases of advanced lung adenocarcinoma and review of literature].
Tao H; Guo L; Tang J; Zhu Y; Xu L; Meng Q; Wu W; Li M; Wu W; Tong L; Wu H; Shi L; Liu Z
Zhongguo Fei Ai Za Zhi; 2014 Apr; 17(4):342-6. PubMed ID: 24758910
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of EGFR-induced glucose metabolism sensitizes chondrosarcoma cells to cisplatin.
Song YD; Zhang KF; Liu D; Guo YQ; Wang DY; Cui MY; Li G; Sun YX; Shen JH; Li XG; Zhang L; Shi FJ
Tumour Biol; 2014 Jul; 35(7):7017-24. PubMed ID: 24748236
[TBL] [Abstract][Full Text] [Related]
17. Profile of erlotinib and its potential in the treatment of advanced ovarian carcinoma.
Hirte HW
Onco Targets Ther; 2013; 6():427-35. PubMed ID: 23723710
[TBL] [Abstract][Full Text] [Related]
18. Omics and therapy - a basis for precision medicine.
Garay JP; Gray JW
Mol Oncol; 2012 Apr; 6(2):128-39. PubMed ID: 22445068
[TBL] [Abstract][Full Text] [Related]
19. Bay846, a new irreversible small molecule inhibitor of EGFR and Her2, is highly effective against malignant brain tumor models.
Longo SL; Padalino DJ; McGillis S; Petersen K; Schirok H; Politz O; Canute GW; Post DE
Invest New Drugs; 2012 Dec; 30(6):2161-72. PubMed ID: 22203214
[TBL] [Abstract][Full Text] [Related]
20. Modeling the transcriptional consequences of epidermal growth factor receptor ablation in Ras-initiated squamous cancer.
Wright LN; Ryscavage A; Merlino G; Yuspa SH
Clin Cancer Res; 2012 Jan; 18(1):170-83. PubMed ID: 22068661
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
